Related Experiment Videos
Comparison of annamycin to adriamycin in cardiac and MDR tumor cell systems
D Kolonias1, T Podona, N Savaraj
1University of Miami, School of Medicine, Department of Cell Biology & Anatomy, Fl. 33136, USA.
Abstract:
Based on the response of a wide variety of tumors to the anthracycline, Adriamycin, numerous studies have been initiated to find an even more effective analog. In this pursuit two of the obstacles that have been necessary to overcome are a unique dose dependent Adriamycin-induced cardiotoxicity reported in patients treated with this chemotherapeutic agent as well as p-gp-mediated multi drug resistance (MDR) which has been found in tumor cells exposed to Adriamycin in vitro and in vivo as well as in human tumor samples. Using an in vitro cardiac cell system and MDR+ and MDR- Friend leukemia cell lines we find that a relatively new anthracycline, Annamycin, has reduced cardiotoxic activity but is more effective in inhibiting the growth of MDR+ cells than Adriamycin. The reduced cardiotoxicity of Annamycin is approximately 10 fold lower than Adriamycin whereas the increased efficacy against the MDR+ Friend leukemia tumor cell line is about 2 fold. The observation that Adriamycin preferentially accumulates in cardiac-muscle (CM) but not in cardiac non-muscle (NM) cells while Annamycin accumulates equally in both, may explain in part the reduced cardiotoxicity of Annamycin. Moreover, the cytosolic accumulation of Annamycin vs the nuclear localization of Adriamycin suggests a different target site for each drug.
Insights
Annamycin, a new anthracycline, shows reduced cardiotoxicity and better efficacy against multi-drug resistant (MDR) cancer cells compared to Adriamycin. This offers a promising alternative for cancer therapy.
Area of Science:
- Oncology
- Pharmacology
- Cardiology
Background:
- Adriamycin is a widely used anthracycline chemotherapy agent.
- Significant challenges include Adriamycin-induced cardiotoxicity and p-glycoprotein-mediated multi-drug resistance (MDR) in tumors.
- Developing novel anthracycline analogs with improved safety and efficacy profiles is crucial.
Purpose of the Study:
- To evaluate the efficacy and cardiotoxicity of Annamycin, a novel anthracycline analog.
- To compare Annamycin's activity against Adriamycin in both cardiac and drug-resistant cancer models.
- To investigate the cellular uptake and localization of Annamycin and Adriamycin.
Main Methods:
- Utilized an in vitro cardiac cell system to assess cardiotoxicity.
- Employed MDR+ and MDR- Friend leukemia cell lines to evaluate anti-cancer efficacy.
- Quantified drug accumulation in cardiac muscle (CM) and non-muscle (NM) cells.
Main Results:
- Annamycin demonstrated approximately 10-fold lower cardiotoxicity compared to Adriamycin.
- Annamycin showed a 2-fold increased efficacy in inhibiting MDR+ Friend leukemia cell growth versus Adriamycin.
- Adriamycin accumulated preferentially in CM cells, while Annamycin distributed equally between CM and NM cells.
Conclusions:
- Annamycin exhibits reduced cardiotoxicity and enhanced efficacy against MDR cancer cells, suggesting its potential as a superior chemotherapeutic agent.
- Differential cellular accumulation and localization may underlie Annamycin's reduced cardiotoxicity.
- Annamycin's distinct cellular behavior indicates a different mechanism of action compared to Adriamycin.